Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Pazdur Believes ‘Advanced Research’ Project Could Address Trial ‘Wastefulness’

Executive Summary

ARPA-H could be a solution to some of FDA’s long-running complaints about US clinical trial infrastructure, the agency's cancer chief says.

You may also be interested in...



Project Pragmatica: US FDA’s OCE Initiative Aims To Encourage Simple Clinical Trials

OCE Director Richard Pazdur says idea for the latest initiative stemmed from a clinical trial in lung cancer that he thought only needed to measure the impact on overall survival.

NIH Director Collins’ Departure May Revive Patent March-In Debate

Confirmation hearing for successor will present opportunity to press the Biden administration on the patent march-in issue, but a policy change seems unlikely—unless the President feels a strong need to act on drug pricing in the absence of legislation.

Biden’s ‘Advanced Research’ Agency May Have Pros And Cons, Congressional Research Service Concludes

CRS poses series of questions about how a new federal agency tasked with speeding translational research for treating high-impact diseases would work, including potential downsides and whether it would duplicate government programs already in place.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel